Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report

Clash for clunkers

Sep 16, 2019

Latest Episodes

Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Download
HTML Embed
HTML EMBED
Click to Copy
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace
Download
HTML Embed
HTML EMBED
Click to Copy
This Is Uncomfortable

Johnson & Johnson hit with $572 million opioid ruling — what happens now?

by David Brancaccio and Redmond Carolipio Aug 27, 2019
Johnson & Johnson is appealing the decision, which could be the first of many legal battles.
A judge has ordered Johnson & Johnson to pay $572 million in connection with the opioid crisis in Oklahoma.
Photo by Mario Tama/Getty Images

Another pharma megamerger: AbbVie buys Allergan for $63 billion

by Erika Beras Jun 25, 2019
Both companies are under pressure to improve their performance.
PHILIPPE HUGUEN/AFP/Getty Images

Congress to examine drug price hikes

by Erika Beras Jan 29, 2019
Prescription drug prices have been rising over the past few years.
jorgeantonio/iStock/Getty Images Plus
Marketplace Tech Blogs

Who owns the results of genetic testing?

by Molly Wood Oct 16, 2018
Personal data from genetic tests has been used in drug development and research.
A visitor views a digital representation of the human genome in 2001 at the American Museum of Natural History in New York City.
Mario Tama/Getty Images
Marketplace Tech Blogs

Who owns the results of genetic testing?

by Molly Wood Oct 16, 2018
Personal data from genetic tests has been used in drug development and research.
A visitor views a digital representation of the human genome in 2001 at the American Museum of Natural History in New York City.
Mario Tama/Getty Images

Generic Viagra floods the market. Here’s how Pfizer is reacting

by Dan Gorenstein Jul 13, 2018
Pfizer hopes to run with its “little blue pill” as long as it can. That includes the time-honored strategy of launching its own generic.
Christopher Furlong/Getty Images

In the midst of a massive opioid crisis, hospitals are experiencing an opioid shortage

by Aaron Schachter May 14, 2018
Drug shortages are nothing new in U.S. hospitals.
Illustration by Emily Judem/WGBH News. Photos courtesy of Benjamin Pennell and Massachusetts General Hospital.

Invest in Marketplace today

Ask not what Marketplace can do for you, but what you can do for Marketplace.

Study shows coupons lead to big profits for drugmakers

by Dan Gorenstein Oct 12, 2016
The question is, who pays?
 
Justin Sullivan/Getty Images

New class of generics could save consumers, insurers billions. FDA is moving carefully.

by Dan Gorenstein Jul 13, 2016
The European Union has some 20 "biosimilar" generics on the market; the US has one.
Pre-filled syringes of  the adalimumab biosimilar.  The biosimilar is used in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis.
SAM PANTHAKY/AFP/Getty Images

What Brexit may mean for the pharmaceutical industry

by Dan Gorenstein Jun 28, 2016
Drug makers are raising concerns Brexit could delay regulatory approval, slow down funding for basic research
British drug makers could face new regulations and road blocks for research as the U.K. prepares to leave the EU. 
Chris Radburn/AFP/Getty Images